| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
The primary target of Torcitabine is viral DNA polymerase (reverse transcriptase). As a nucleoside analog, it is incorporated into viral DNA during replication, acting as a chain terminator. This inhibits the synthesis of viral DNA, especially having a greater inhibitory effect on the synthesis of the first strand of DNA than the second strand. The compound is a nucleoside inhibitor active against hepatitis B virus. It also exhibits activity against HIV.
|
|---|---|
| ln Vitro |
First strand DNA synthesis is more inhibited by toracitbine (2'-Deoxy-L-cytidine) than second strand DNA synthesis.
In vitro, Torcitabine has shown antiviral potency. It exhibits greater inhibition of first strand than second strand DNA synthesis. The compound has been shown to inhibit the growth of bacteria that are resistant to tetracycline, such as Mycobacterium tuberculosis and Helicobacter pylori. However, its antiviral activity has not been fully evaluated in vivo. |
| ln Vivo |
In vivo, Torcitabine has the potential for chronic hepatitis B virus infection treatment. It showed promise in early studies for reducing viral load, particularly in cases resistant to other antiviral therapies. However, due to toxicity concerns, its development for HIV and HBV treatment has been limited. Despite these challenges, torcitabine remains a molecule of interest in antiviral research.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for Torcitabine involve measuring its inhibition of viral DNA polymerase activity. The assay uses purified recombinant HBV or HIV reverse transcriptase and a template-primer substrate. The incorporation of radiolabeled nucleotides into the growing DNA chain is measured. The compound is incubated with the enzyme and substrate at varying concentrations to determine the IC50.
|
| Cell Assay |
In vitro cell-based assays for Torcitabine are performed using HBV-infected or HIV-infected cell lines. Cells are treated with the compound, and viral replication is measured by quantifying viral DNA or RNA using PCR or Southern blotting. Cytotoxicity is assessed using standard cell viability assays. The compound's effects on viral DNA synthesis and chain termination are evaluated.
|
| Animal Protocol |
In vivo animal experiments for Torcitabine are limited due to toxicity concerns. Early studies showed promise in reducing viral load in animal models of HBV infection. However, detailed protocols for in vivo studies are not well-documented. The compound is typically administered orally or intravenously in preclinical studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Torcitabine indicate that it has a molecular weight of 227.22 and a molecular formula of C9H13N3O4. It has a purity of ≥95%. The IUPAC name is 4-amino-1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one. The compound is a nucleoside analog. Storage at -20°C is recommended.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for Torcitabine indicate that it has toxicity concerns that have limited its development. The compound's safety profile in the context of therapeutic use requires further evaluation. The compound is for research use only and not for human therapeutic use.
|
| References | |
| Additional Infomation |
Tocilitabine is a nucleoside inhibitor active against hepatitis B virus. In vivo, tocilitabine is modified into a triphosphate form and acts as a competitive inhibitor of viral DNA polymerase.
Other information: Torcitabine is also known as 2'-Deoxy-L-cytidine, L-dC, BCH-189, and NV-02C. It is a beta-L-enantiomer nucleoside analog. The compound was developed by Idenix (Originator). It has the potential for chronic hepatitis B virus infection research. Its CAS number is 40093-94-5. |
| Molecular Formula |
C9H13N3O4
|
|---|---|
| Molecular Weight |
227.22
|
| Exact Mass |
227.091
|
| Elemental Analysis |
C, 47.57; H, 5.77; N, 18.49; O, 28.16
|
| CAS # |
40093-94-5
|
| PubChem CID |
159354
|
| Appearance |
White to off-white solid powder
|
| Density |
1.73 g/cm3
|
| Boiling Point |
497.6ºC at 760 mmHg
|
| Flash Point |
254.8ºC
|
| Index of Refraction |
1.719
|
| LogP |
-1.8
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
355
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O=C1N=C(N)C=CN1[C@@H]2O[C@@H](CO)[C@H](O)C2
|
| InChi Key |
CKTSBUTUHBMZGZ-CHKWXVPMSA-N
|
| InChi Code |
InChI=1S/C9H13N3O4/c10-7-1-2-12(9(15)11-7)8-3-5(14)6(4-13)16-8/h1-2,5-6,8,13-14H,3-4H2,(H2,10,11,15)/t5-,6+,8+/m1/s1
|
| Chemical Name |
4-amino-1-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
|
| Synonyms |
Torcitabine; L-dC; Torcitabine; L-Deoxycytidine; NV-02C; NV 02C; NV02C;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1100.26 mM )
H2O : ~250 mg/mL (~1100.26 mM ) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.08 mg/mL (9.15 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4010 mL | 22.0051 mL | 44.0102 mL | |
| 5 mM | 0.8802 mL | 4.4010 mL | 8.8020 mL | |
| 10 mM | 0.4401 mL | 2.2005 mL | 4.4010 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
